Karyopharm Therapeutics Inc. (KPTI)
2025-06-30 | 2025-03-31 | 2024-09-30 | ||
|---|---|---|---|---|
| Revenue from contract with customer, license and other revenue | 37,929 | 30,015 | 38,783 | |
| Cost of sales | - | 1,301 | 1,300 | |
| Selling, general and administrative | 28,477 | 27,352 | 27,632 | |
| Research and development | 32,788 | 34,618 | 36,134 | |
| Cost of sales-Product | 1,051 | - | - | |
| Total operating expenses | 62,316 | 63,271 | 65,066 | |
| Loss from operations | -24,387 | -33,256 | -26,283 | |
| Other (expense) income, net | -2,210 | 19,824 | 3,792 | |
| Interest income | 613 | 1,000 | 1,832 | |
| Interest expense | 11,228 | 10,994 | 11,385 | |
| Gain on extinguishment of debt | - | - | - | |
| Total other income (expense), net | -12,825 | 9,830 | -5,761 | |
| (loss) income before income taxes | -37,212 | -23,426 | -32,044 | |
| Income tax provision | 40 | 36 | 28 | |
| Net (loss) income | -37,252 | -23,462 | -32,072 | |
| Basic net income (loss) per common share ( a / b) | -4.32 | -2.77 | -0.26 | |
| Earnings per share, diluted, total | -4.32 | -2.77 | -0.26 | |
| Weighted average number of shares outstanding, basic | 8,620 | 8,470 | 125,010 | |
| Weighted-average number of common shares outstanding used to compute diluted net loss per share | 8,620 | 8,470 | 125,010 | |